Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6494MR)

This product GTTS-WQ6494MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6494MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9963MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ13580MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ3639MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ1276MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ7563MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ13337MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ3554MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ8770MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW